Clinical Trial Update: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating autologous CD19-targeted T cells (CAR-T) for relapsed or chemotherapy-refractory chronic lymphocytic leukemia and indolent B-cell lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent B-cell Lymphoma

Drugs mentioned

• Autologous CD19-targeted T cells (Chimeric antigen receptor T cells targeting CD19)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING